EUVIMEDEUVIMED entdecken
Crossref

EP3 receptor mediates calcium oxalate kidney stone formation via Ca²⁺/AKT and necroinflammation

Jing Leng, Yang Li, Xueqing Tang, Zhijie Song, Hangyu Lv, Huiying Han, Na Wen, Jinghang Fan, Xin Zhang A, Lin Zhang, Xin Zhang B, Fabin Zhou und 3 weitere

Urolithiasis · 14.08.2026 · 54 (1)

DOI: 10.1007/s00240-026-02030-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urolithiasis, online erschienen am 14.08.2026. Verfasst von Jing Leng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Genetics, Shenyang Medical College, Shenyang, 110034, China. Hauptthemen laut MEDLINE: Calcium Oxalate, Proto-Oncogene Proteins c-akt, Receptors, Prostaglandin E, EP3 Subtype, Kidney Calculi. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Doctoral Research Startup Project of the Liaoning Provincial Science and Technology Plan Joint Fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney stone disease is a prevalent urological condition with rising incidence and high recurrence rates, yet effective pharmacological interventions remain lacking [1] Prostaglandin E₂ (PGE₂) and its receptor EP3 have been implicated in inflammatory kidney injury [1-3], but their role in nephrolithiasis is unclear. This study investigates the role and mechanism of EP3 in calcium oxalate (CaOx) stone formation using in vitro and in vivo models. EP3 expression was significantly upregulated in CaOx-stimulated human renal tubular epithelial cells (HK-2) and in kidney tissues of glyoxylate-induced nephrolithiasis mice. Treatment with the EP3 antagonist DG041 in vitro reduced crystal adhesion, decreased HMGB1 release, and suppressed IL-6 and TNF-α expression. Mechanistically, EP3 antagonism inhibited aberrant intracellular Ca2⁺ elevation and reduced AKT phosphorylation. Virtual screening identified Astragaloside A as a potential EP3 inhibitor. Astragaloside A recapitulated the protective effects of DG041, attenuating crystal adhesion, inflammation, and necroinflammation both in vitro and in vivo. These findings indicate that EP3 mediates crystal-induced renal tubular injury and inflammation via the Ca2⁺/AKT signaling axis. Targeting EP3 may interrupt the "crystal‑injury‑inflammation" cycle in nephrolithiasis, offering a new therapeutic strategy. This study is the first to demonstrate that the EP3 receptor mediates calcium oxalate kidney stone formation through the Ca2⁺/AKT signaling pathway and necroinflammation. EP3 antagonism reduces crystal adhesion, HMGB1 release, and inflammation. Virtual screening identifies astragaloside A as a novel EP3 inhibitor with protective effects in vitro and in vivo, highlighting EP3 as a promising therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium OxalateProto-Oncogene Proteins c-aktReceptors, Prostaglandin E, EP3 SubtypeKidney CalculiNephrolithiasisAnimalsHumansMiceMaleCalciumHMGB1 ProteinDisease Models, AnimalCell LineInflammationTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Calcium oxalateEP3 receptorKidney stonesNecroinflammation

Substanzen

Calcium OxalateProto-Oncogene Proteins c-aktReceptors, Prostaglandin E, EP3 SubtypeCalciumHMGB1 ProteinTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Cell Biology and Genetics, Shenyang Medical College, Shenyang, 110034, China.
  • Key Laboratory of Renal Calcification Disease Prevention and Treatment, 146 Huanghe North Street, Shenyang, 110034, China.
  • Shenyang Red-cross Hospital, 389 Zhongshan Rd, Shenyang, 110013, China.
  • Department of Cell Biology and Genetics, Shenyang Medical College, Shenyang, 110034, China. gaobingdr@hotmail.com.
  • Key Laboratory of Renal Calcification Disease Prevention and Treatment, 146 Huanghe North Street, Shenyang, 110034, China. gaobingdr@hotmail.com.

Förderung

  • Doctoral Research Startup Project of the Liaoning Provincial Science and Technology Plan Joint Fund
  • National Natural Science Foundation of China

Zitieren

APA

Leng, J., Li, Y., Tang, X., Song, Z., Lv, H., Han, H., Wen, N., Fan, J., Zhang A, X., Zhang, L., Zhang B, X., Zhou, F., Guo, T., Liu, Q., & Gao, B. (2026). EP3 receptor mediates calcium oxalate kidney stone formation via Ca²⁺/AKT and necroinflammation. Urolithiasis, 54(1). https://doi.org/10.1007/s00240-026-02030-0

Vancouver

Leng J, Li Y, Tang X, Song Z, Lv H, Han H, et al. EP3 receptor mediates calcium oxalate kidney stone formation via Ca²⁺/AKT and necroinflammation. Urolithiasis. 2026;54(1). doi:10.1007/s00240-026-02030-0

BibTeX
@article{Leng2026,
  author = {Leng, Jing and Li, Yang and Tang, Xueqing and Song, Zhijie and Lv, Hangyu and Han, Huiying and Wen, Na and Fan, Jinghang and Zhang A, Xin and Zhang, Lin and Zhang B, Xin and Zhou, Fabin and Guo, Tao and Liu, Qing and Gao, Bing},
  title = {EP3 receptor mediates calcium oxalate kidney stone formation via Ca²⁺/AKT and necroinflammation},
  journal = {Urolithiasis},
  year = {2026},
  volume = {54},
  number = {1},
  doi = {10.1007/s00240-026-02030-0}
}
Kostenlos starten →